Recursos sobre trasplantes
Trasplante renal: Artículos interesantes

Esther González Monte. Tratamiento del Hiperparatiroidismo secundario en el trasplante renal

H. Amer, M. D. Griffin, M. D. Stegall, F. G. Cosio, W. D. Park, W. K. Kremers, R. L. Heilman, M. J. Mazur, K. Hamawi, T. S. Larson and R. Kumar. Oral Paricalcitol Reduces the Prevalence of Posttransplant Hyperparathyroidism: Results of an Open Label Randomized Trial. American Journal of Transplantation 2013; XX: 1-10 Wiley Periodicals Inc.

González. Effects of Oral Paricalcitol on Secondary Hyperparathyroidism and Proteinuria of Kidney Transplant Patients. 2013 Lippincott Williams & Wilkins

Vanessa Pérez, Anna Sánchez-Escuredo, Ricardo Lauzurica, Beatriu Bayés, Maribel Navarro-Muñoz, María Cruz Pastor, Laura Cañas, Josep Bonet, Ramón Romero González. Magnetic bead-based proteomic technology to study paricalcitol effect in kidney transplant recipients. European Journal of Pharmacology Volume 709, Issues 1-3, 5 June 2013, Pages 72-79

Rostaing L, Vincenti F, Grinyó J, Rice KM, Bresnahan B, Steinberg S, Gang S, Gaite LE, Moal MC, Mondragón-Ramirez GA, Kothari J, Pupim L, Larsen CP. Long-Term Belatacept Exposure Maintains Efficacy and Safety at 5 Years: Results From the Long-Term Extension of the BENEFIT Study. Am J Transplant 2013 Sep 18. [Epub ahead of print].

Suthanthiran M, Schwartz JE, Ding R, Abecassis M, Dadhania D, Samstein B, Knechtle SJ, Friedewald J, Becker YT, Sharma VK, Williams NM, Chang CS, Hoang C, Muthukumar T, August P, Keslar KS, Fairchild RL, Hricik DE, Heeger PS, Han L, Liu J, Riggs M, Ikle DN, Bridges ND, Shaked A; Clinical Trials in Organ Transplantation 04 (CTOT-04) Study Investigators. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med 2013 Jul 4; 369 (1): 20-31.

Rostaing L, Charpentier B, Glyda M, Rigotti P, Hettich F, Franks B, Houbiers JG, First R, Holman JM. Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial. Am J Transplant 2013 Jul; 13 (7): 1724-33.

Welberry Smith MP, Cherukuri A, Newstead CG, Lewington AJ, Ahmad N, Menon K, Pollard SG, Prasad P, Tibble S, Giddings E, Baker RJ. Alemtuzumab Induction in Renal Transplantation Permits Safe Steroid Avoidance with Tacrolimus Monotherapy: A Randomized Controlled Trial. Transplantation 2013 Sep 19.

Rostaing L, Charpentier B, Glyda M, Rigotti P, Hettich F, Franks B, Houbiers JG, First R, Holman JM. Alefacept Combined With Tacrolimus, Mycophenolate Mofetil and Steroids in De Novo Kidney Transplantation: A Randomized Controlled Trial. Am J Transplant. 2013 Jun 3.

Gaber AO, Moore LW, Alloway RR, Woodle ES, Pirsch J, Shihab F, Henning A, Fitzsimmons W, Holman J, Reisfield R, First MR. Acute rejection characteristics from a prospective, randomized, double-blind, placebo-controlled multicenter trial of early corticosteroid withdrawal; Astellas Corticosteroid Withdrawal Study Group. Transplantation 2013 Feb 27; 95 (4): 573-9.

Cibrik D, Silva HT Jr, Vathsala A, Lackova E, Cornu-Artis C, Walker RG, Wang Z, Zibari GB, Shihab F, Kim YS. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation 2013 Apr 15; 95 (7): 933-42.

Wang X, Qin X, Wang Y, Huang Z, Li X, Zeng Q, Zeng H, Lu Y, Wang L, Lin T. Controlled-Dose Versus Fixed-Dose Mycophenolate Mofetil for Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Transplantation 2013 Apr 3.

Kawai T, Sachs DH, Sykes M, Cosimi AB. HLA-mismatched renal transplantation without maintenance immunosuppression; Immune Tolerance Network. N Engl J Med. 2013 May.

Kaabak MM, Babenko NN, Samsonov DV, Sandrikov VA, Maschan AA, Zokoev AK. Alemtuzumab induction in pediatric kidney transplantation. Pediatr Transplant 2013 Mar; 17 (2): 168-78. doi: 10.1111/petr.12048

Suszynski TM, Gillingham KJ, Rizzari MD, Dunn TB, Payne WD, Chinnakotla S, Finger EB, Sutherland DE, Najarian JS, Pruett TL, Matas AJ, Kandaswamy R. Prospective Randomized Trial of Maintenance Immunosuppression With Rapid Discontinuation of Prednisone in Adult Kidney Transplantation. Am J Transplant 2013 Feb 22. doi: 10.1111/ajt.1216

Barnett AN, Hadjianastassiou VG, Mamode N. Rituximab in renal transplantation. Transpl Int 2013 Feb 18. doi: 10.1111/tri.12072.

Sarwal MM, Ettenger RB, Dharnidharka V, Benfield M, Mathias R, Portale A, McDonald R, Harmon W, Kershaw D, Vehaskari VM, Kamil E, Baluarte HJ, Warady B, Tang L, Liu J, Li L, Naesens M, Sigdel T, Waskerwitz J, Salvatierra O. Complete steroid avoidance is effective and safe in children with renal transplants: a multicenter randomized trial with three-year follow-up. Am J Transplant 2012 Oct; 12 (10): 2719-29

Ojo AO, Morales JM, González-Molina M, Steffick DE, Luan FL, Merion RM, Ojo T, Moreso F, Arias M, Campistol JM, Hernández D, Serón D; Scientific Registry of Transplant Recipients and Spanish Chronic Allograft Study Group Comparison of the long-term outcomes of kidney transplantation: USA versus Spain. Nephrol Dial Transplant 2013 Jan; 28 (1): 213-20.

Tacrolimus-Based, Steroid-Free Regimens in Renal Transplantation: 3-Year Follow-up of the ATLAS Trial

Monitoring of Immunoglobulin Levels Identifies Kidney Transplant Recipients at High Risk of Infection

Improved Renal Function After Early Conversion From a Calcineurin Inhibitor to Everolimus: a Randomized Trial in Kidney Transplantation

Sirolimus and secondary skin-cancer prevention in kidney transplantation

Kidney Function and Risk of Cardiovascular Disease and Mortality in Kidney Transplant Recipients: The FAVORIT Trial

Antibody-mediated rejection in kidney transplantation: a review

Summary of the British Transplantation Society/Renal Association U.K. guidelines for living donor kidney transplantation

A Risk-Prediction Model for In-hospital Mortality After Heart Transplantation in US Children

Three-Year Outcomes From BENEFIT-EXT: A Phase III Study of Belatacept Versus Cyclosporine in Recipients of Extended Criteria Donor Kidneys

Outcomes of ABO-Incompatible Kidney Transplantation in the United States

Everolimus as primary immunosuppression in kidney transplantation: experience in conversion from calcineurin inhibitors

The once-daily formulation of tacrolimus: a step forward in kidney transplantation?

Long-Term Experience With Kidney Transplantation From Hepatitis C-Positive Donors Into Hepatitis C-Positive Recipients

Systematic screening and treatment of asymptomatic bacteriuria in renal transplant recipients

Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation

Tolerance and Chimerism after Renal and Hematopoietic-Cell Transplantation

Green Urine

Case 8-2008 — A 33-Year-Old Man with Fever, Abdominal Pain, and Pancytopenia after Renal Transplantation

Chronic Hepatitis E with Cirrhosis in a Kidney-Transplant Recipient

Hepatitis E Virus and Chronic Hepatitis in Organ-Transplant Recipients

HLA-Mismatched Renal Transplantation without Maintenance Immunosuppression

Early Events in Kidney Donation: Progression of Endothelial Activation, Oxidative Stress and Tubular Injury After Brain Death

Comparing Microarray Versus RT-PCR Assessment of Renal Allograft Biopsies: Similar Performance Despite Different Dynamic Ranges

Partial Bladder Transplantation with En Bloc Kidney Transplant—The First Case Report of a ‘Bladder Patch Technique’ in a Human

Clinical Relevance of Pretransplant Donor-Directed Antibodies Detected by Single Antigen Beads in Highly Sensitized Renal Transplant Patients

Calculating life years from transplant (LYFT): methods for kidney and kidney-pancreas candidates

Banff 07 classification of renal allograft pathology: updates and future directions

Monocyte infiltration and kidney allograft dysfunction during acute rejection